The KIDSTEM European Research Training Network: Developing a Stem Cell Based Therapy to Replace Nephrons Lost through Reflux Nephropathy

P Murray, G Camussi, Jamie Davies, D Edgar, M Hengstschlager, S Kenny, G Remuzzi and C Werner

volume 3 | issue 1

jan/feb/march 2007

We now provide open access to journal articles published online for one year or more. This article may be downloaded at the following link:

Download PDF

If the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.

The incidence and prevalence of end stage renal disease (ESRD) continues to grow worldwide at a rate that is far in excess of the growth rate of the general population. In children and young adults the most common cause of ESRD is vesicoureteric reflux (VUR), a condition where urine from the bladder re-enters the kidney, predisposing to pyelonephritis, renal scarring, and in the most severe cases, ESRD. However, there is usually a time-window of several years from initial diagnosis of VUR to the development of ESRD, which presents an opportunity to design therapies aimed at preventing disease progression by repairing renal tissue before it becomes non-functional. Advances in our understanding of kidney development coupled with recent progress in stem cell science and tissue engineering, present an unprecedented opportunity to design a stem cell-based therapy for this clinical problem. KIDSTEM will investigate the properties of several different stem cell types (kidney stem cells, embryonic stem cells, amniotic fluid stem cells and mesenchymal stem cells) to determine which is most appropriate for the generation of functional renal tissue promoted by specifically designed biomaterials to facilitate the generation of functional nephrons.

Authors

P Murray

School of Biological Sciences; University of Liverpool; Liverpool, UK

G Camussi

Department of Internal Medicine/Laboratory of Renal Immunopathology; Universita' Degli Studi di Torino; Turin, Italy

Jamie Davies

University of Edinburgh Medical School; Edinburgh; UK

D Edgar

School of Biomedical Sciences; University of Liverpool; Liverpool, UK

M Hengstschlager

Medical University of Vienna; Vienna, Austria

S Kenny

Institute of Child Health; University of Liverpool and Alder Hey Children’s Hospital, Liverpool, UK

G Remuzzi

Department of Molecular Medicine/Mario Negri Institute for Pharmacological Research; Istituto di Ricerche Farmacologiche Mario Negri; Bergamo, Italy

C Werner

Max Bergmann Center of Biomaterials Dresden; Leibniz-Institut fur Polymerforschung Dresden e.V.; Dresden, Germany

We now provide open access to journal articles published online for one year or more. This article may be downloaded at the following link: